Work

Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps1134

Authors: Neelima Vidula, Senthil Damodaran, Manali A. Bhave, Hope S. Rugo, Erica Blouch, Nathan Royce Ruffle-Deignan, Ami N. Shah, Massimo Cristofanilli, Vandana G Abramson, Joseph A. Sparano, Harry Ostrer, Nora K. Horick, Aditya Bardia

Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Emory University, University of California, San Francisco, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Weill Cornell Medicine, Vanderbilt University, Tisch Cancer Institute, Albert Einstein College of Medicine

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Conquer Cancer Foundation

OpenAlex ID: W4379328288

Cites:

Cited by: 4

Related to: 10